NLS Pharmaceutics (NASDAQ:NCEL) Director Michel Revel Buys 54,545 Shares

NLS Pharmaceutics Ltd. (NASDAQ:NCEL) Director Michel Revel bought 54,545 shares of the firm’s stock in a transaction dated Monday, April 27th. The stock was purchased at an average cost of $2.75 per share, for a total transaction of $149,998.75. Following the transaction, the director directly owned 957,530 shares of the company’s stock, valued at $2,633,207.50. The trade was a 6.04% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

NLS Pharmaceutics Price Performance

Shares of NLS Pharmaceutics stock traded up $0.07 on Wednesday, hitting $3.42. The stock had a trading volume of 20,242 shares, compared to its average volume of 83,584. NLS Pharmaceutics Ltd. has a twelve month low of $1.83 and a twelve month high of $30.80. The business’s 50 day moving average is $2.72 and its two-hundred day moving average is $4.14.

NLS Pharmaceutics Company Profile

NLS Pharmaceutics (NASDAQ: NCEL) is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, with additional operations in the United States. The company focuses on the development of small-molecule therapies designed to address disorders of the circadian rhythm and sleep-wake cycle. It leverages proprietary controlled-release and receptor-targeting approaches to optimize drug exposure over a 24-hour period.

The core of NLS Pharmaceutics’ pipeline consists of novel melatonin receptor agonists aimed at treating rare and orphan sleep disorders such as non-24-hour sleep-wake disorder and idiopathic hypersomnia.